{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,7]],"date-time":"2026-10-07T07:01:12Z","timestamp":1791356472412,"version":"4.3.1"},"reference-count":18,"publisher":"Elsevier BV","issue":"3","license":[{"start":{"date-parts":[[2007,3,1]],"date-time":"2007-03-01T00:00:00Z","timestamp":1172707200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2007,3,1]],"date-time":"2007-03-01T00:00:00Z","timestamp":1172707200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Epilepsy Research"],"published-print":{"date-parts":[[2007,3]]},"DOI":"10.1016\/j.eplepsyres.2006.11.005","type":"journal-article","created":{"date-parts":[[2007,1,25]],"date-time":"2007-01-25T10:06:10Z","timestamp":1169719570000},"page":"275-283","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":28,"title":["Distinct absorption characteristics of oral formulations of valproic acid\/divalproex available in the United States"],"prefix":"10.1016","volume":"73","author":[{"given":"Sandeep","family":"Dutta","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ronald C.","family":"Reed","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"issue":"8","key":"10.1016\/j.eplepsyres.2006.11.005_bib1","doi-asserted-by":"crossref","first-page":"743","DOI":"10.1002\/j.1552-4604.1990.tb03637.x","article-title":"Absorption characteristics of a new valproate formulation: divalproex sodium-coated particles in capsules (Depakote\u00ae Sprinkle)","volume":"30","author":"Carrigan","year":"1990","journal-title":"J. Clin. Pharmacol."},{"issue":"Suppl. 8","key":"10.1016\/j.eplepsyres.2006.11.005_bib2","first-page":"54","article-title":"Effect of food on the bioavailability of a controlled-release formulation of Depakote under multiple-dose conditions.","volume":"38","author":"Cavanaugh","year":"1997","journal-title":"Epilepsia"},{"issue":"1","key":"10.1016\/j.eplepsyres.2006.11.005_bib3","doi-asserted-by":"crossref","first-page":"30","DOI":"10.1002\/j.1552-4604.1980.tb01663.x","article-title":"Bioavailability of valproic acid under fasting\/nonfasting regimens","volume":"20","author":"Chun","year":"1980","journal-title":"J. Clin. Pharmacol."},{"issue":"4, Pt. 1","key":"10.1016\/j.eplepsyres.2006.11.005_bib4","doi-asserted-by":"crossref","first-page":"634","DOI":"10.1016\/S0022-3476(05)82496-5","article-title":"Comparison of sprinkle versus syrup formulations of valproate for bioavailability, tolerance, and preference","volume":"120","author":"Cloyd","year":"1992","journal-title":"J. Pediatr."},{"key":"10.1016\/j.eplepsyres.2006.11.005_bib5","unstructured":"Depakene\u00ae Product Information, 2003. Depakene\u00ae Valproic Acid Capsules and Syrup. Abbott Laboratories, Inc., North Chicago, IL, USA."},{"key":"10.1016\/j.eplepsyres.2006.11.005_bib6","unstructured":"Depakote\u00ae ER Tablets Product Information, 2005. Divalproex Sodium Extended-Release Tablets. Abbott Laboratories, Inc., North Chicago, IL, USA."},{"key":"10.1016\/j.eplepsyres.2006.11.005_bib7","unstructured":"Depakote\u00ae Sprinkle Capsules Product Information, 2003. Divalproex Sodium Coated Particles in Capsules. Abbott Laboratories, Inc., North Chicago, IL, USA."},{"key":"10.1016\/j.eplepsyres.2006.11.005_bib8","unstructured":"Depakote\u00ae Tablets Product Information, 2004. Divalproex Sodium Delayed-Release Tablets. Abbott Laboratories, Inc., North Chicago, IL, USA."},{"issue":"7","key":"10.1016\/j.eplepsyres.2006.11.005_bib9","doi-asserted-by":"crossref","first-page":"737","DOI":"10.1177\/0091270004266782","article-title":"Absolute bioavailability and absorption characteristics of divalproex sodium extended-release tablets in healthy volunteers","volume":"44","author":"Dutta","year":"2004","journal-title":"J. Clin. Pharmacol."},{"issue":"8","key":"10.1016\/j.eplepsyres.2006.11.005_bib10","doi-asserted-by":"crossref","first-page":"345","DOI":"10.1002\/bdd.420","article-title":"Bioavailability of divalproex extended-release formulation relative to the divalproex delayed-release formulation","volume":"25","author":"Dutta","year":"2004","journal-title":"Biopharm. Drug Dispos."},{"issue":"9","key":"10.1016\/j.eplepsyres.2006.11.005_bib11","doi-asserted-by":"crossref","first-page":"495","DOI":"10.2165\/00044011-200424090-00001","article-title":"Divalproex to divalproex extended release conversion","volume":"24","author":"Dutta","year":"2004","journal-title":"Clin. Drug Invest."},{"issue":"8","key":"10.1016\/j.eplepsyres.2006.11.005_bib12","doi-asserted-by":"crossref","first-page":"353","DOI":"10.1002\/bdd.421","article-title":"Comparison of the bioavailability of 250 and 500mg divalproex sodium extended-release tablets in healthy volunteers","volume":"25","author":"Dutta","year":"2004","journal-title":"Biopharm. Drug Dispos."},{"key":"10.1016\/j.eplepsyres.2006.11.005_bib13","doi-asserted-by":"crossref","first-page":"619","DOI":"10.1345\/aph.1G617","article-title":"Comparative absorption profiles of divalproex sodium delayed-release versus extended-release tablets \u2013 Clinical implications","volume":"40","author":"Dutta","year":"2006","journal-title":"Ann. Pharmacother."},{"key":"10.1016\/j.eplepsyres.2006.11.005_bib14","doi-asserted-by":"crossref","first-page":"952","DOI":"10.1177\/0091270006289480","article-title":"A multiphasic absorption model best characterizes gastrointestinal absorption of divalproex sodium extended-release tablets","volume":"46","author":"Dutta","year":"2006","journal-title":"J. Clin. Pharmacol."},{"key":"10.1016\/j.eplepsyres.2006.11.005_bib15","unstructured":"FDA Orange Book, 2006. http:\/\/www.accessdata.fda.gov\/scripts\/cder\/ob\/docs\/tempai.cfm, keywords \u201cvalproic acid\u201d and \u201cdivalproex\u201d, accessed March 27."},{"issue":"8","key":"10.1016\/j.eplepsyres.2006.11.005_bib16","doi-asserted-by":"crossref","first-page":"1319","DOI":"10.1212\/WNL.38.8.1319","article-title":"Effect of food on the serum concentration profile of enteric-coated valproic acid","volume":"38","author":"Fischer","year":"1988","journal-title":"Neurology"},{"key":"10.1016\/j.eplepsyres.2006.11.005_bib17","series-title":"Pharmacokinetics","author":"Gibaldi","year":"1982"},{"issue":"7","key":"10.1016\/j.eplepsyres.2006.11.005_bib18","doi-asserted-by":"crossref","first-page":"754","DOI":"10.1002\/j.1552-4604.1994.tb02036.x","article-title":"Pharmacokinetics of valproate after multiple-dose oral and intravenous infusion administration: gastrointestinal-related diurnal variation","volume":"34","author":"Hussein","year":"1994","journal-title":"J. Clin. Pharmacol."}],"container-title":["Epilepsy Research"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0920121106004451?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0920121106004451?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,10,12]],"date-time":"2025-10-12T13:17:00Z","timestamp":1760275020000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0920121106004451"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2007,3]]},"references-count":18,"journal-issue":{"issue":"3","published-print":{"date-parts":[[2007,3]]}},"alternative-id":["S0920121106004451"],"URL":"https:\/\/doi.org\/10.1016\/j.eplepsyres.2006.11.005","relation":{},"ISSN":["0920-1211"],"issn-type":[{"value":"0920-1211","type":"print"}],"subject":[],"published":{"date-parts":[[2007,3]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Distinct absorption characteristics of oral formulations of valproic acid\/divalproex available in the United States","name":"articletitle","label":"Article Title"},{"value":"Epilepsy Research","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.eplepsyres.2006.11.005","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"Copyright \u00a9 2006 Elsevier B.V. All rights reserved.","name":"copyright","label":"Copyright"}]}}